Shot in the arm for HIV/Aids treatment and for public-private partnerships in South Africa

25 February 2010

South Africa's Treasury has set aside an extra 8.4 billion rands ($1.09 billion) for HIV/AIDS over the next three years, reflecting its commitment to improving the quality of services for people affected by the disease and doubling the number of patients getting life-saving antiretroviral therapy, reports the local newspaper, the Business Daily.

Conditional grants to the provinces for HIV/AIDS are set to rise from 6.01 billion rands in fiscal 2010-11 to 7.43 billion rands in 2011-12 and 8.77 billion rands in 2012-13. These are ring-fenced grants that are transferred to the provinces via the national Department of Health and cannot be used for any other purpose, the newspaper notes.

The country's President, Jacob Zuma, announced last December that the government would introduce new HIV treatment guidelines by April 1, allowing patients who are pregnant or infected with TB to start treatment when their CD4 count, which measures the strength of the immune system, falls to 350, instead of waiting until it reaches 200. All HIV-infected babies are to get treatment straightaway, instead of waiting until they get sick. According to the Treasury, the new measures will save an extra 10,000 lives a year.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Pharmaceutical